PLM60 Plus Pegaspargase Shows Promise in Extranodal Natural Killer and T-Cell Lymphoma
Researchers sought to determine whether PLM60 with pegaspargase would have efficacy in patients with extranodal natural killer/T-cell lymphoma.
Lymphoma
Genomic Features and Anti-CD19 CAR-T Therapy Failure in Large B-Bell Lymphoma
Researchers sought to identify genomic features in patients with large B-cell lymphoma that are linked with anti-CD19 CAR-T therapy.
Cutaneous T-Cell Lymphoma Incidence on the Rise in the United States
The incidence of cutaneous T-cell lymphoma in the United States increased from 2000 to 2018, with an annual percent change of 0.61%.
Risk Prediction Models Identify Hodgkin Lymphoma Survivors at Risk for CVD
Researchers sought to determine risk predictors for coronary heart disease and heart failure in Hodgkin lymphoma survivors who were aged 18 to 50 at diagnosis.
Coagulation Parameters With Cytokine-Release Syndrome and CAR-T Therapy in B-Cell Lymphomas
Researchers sought to determine patterns in coagulation parameters linked to cytokine-release syndrome in patients receiving CAR-T therapy.
First-Line Brentuximab Vedotin With AVD Improves Survival in Stage III or IV Hodgkin Lymphoma
Researchers sought to determine whether adding brentuximab vedotin to AVD would improve survival in patients with stage III or IV Hodgkin lymphoma.
Hodgkin Lymphoma Treatment Regimens
Find comprehensive treatment regimens for Hodgkin lymphoma, including therapies such as ABVD + involved-field radiotherapy and more.
Incidence of Cutaneous T-Cell Lymphoma Up in the U.S.
Overall incidence rate six times higher for patients aged 40 years or older versus younger than 40 years, but increase in CTCL rate significantly higher for those younger than 40 years.
Pemazyre Approved for Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement
The approval was based on data from the phase 2 FIGHT-203 study, which included 28 patients with relapsed or refractory myeloid/lymphoid neoplasms with FGFR1 rearrangement.
Acute Kidney Injury After CAR-T Therapy for Non-Hodgkin Lymphoma
Researchers sought to determine the incidence and possible risk factors of acute kidney injury in patients undergoing a chimeric antigen receptor T-cell therapy for non-Hodgkin lymphoma.
- Loading...
Loading...
Next post in Lymphoma
Loading... 
Loading...